

Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma

NOBUHIKO NAKAGAWA*, FUMINORI SONOHARA, KATSUHITO TANAKA*, YUKI SUNAGAWA, YOSHIKUNI INOKAWA, HIDEKI TAKAMI, MASAMICHI HAYASHI, SUGURU YAMADA, MITSURO KANDA, CHIE TANAKA, GORO NAKAYAMA, MASAHICO KOIKE and YASUHIRO KODERA

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan

Received February 15, 2021; Accepted May 4, 2021

DOI: 10.3892/ol.2021.12799

Abstract. N⁶-methyladenosine (m⁶A), the most abundant internal RNA modification, serves a critical role in cancer development. However, the clinical implications of m⁶A in hepatocellular carcinoma (HCC) remain unclear. The present study sought to reveal the potential roles of m⁶A readers, which recognize m⁶A, in HCC. A total of 177 HCC and paired non-cancerous liver tissues from patients who underwent hepatectomy were analysed using quantitative PCR for the expression of m⁶A readers: YT521-B homology domain family 1 (*YTHDF1*) and YT521-B homology domain family 2 (*YTHDF2*). The expression levels of both *YTHDF1* and *YTHDF2* were not significantly different between tumour and non-cancerous tissues (P=0.93 and P=0.7, respectively). Analysis of the association between clinical features and m⁶A reader expression revealed that *YTHDF1* expression was associated with formation of capsule (P=0.02), whereas low *YTHDF2* expression was associated with septal formation (P=0.02). Furthermore, high *YTHDF1* expression and high *YTHDF2* expression were significantly associated with shorter recurrence-free survival (RFS) [*YTHDF1*: Mean survival time (MST), 34.0 vs. 19.0 months, P=0.014; *YTHDF2*: MST, 30.1 vs. 12.9 months, P=0.0032], whereas *YTHDF1* and *YTHDF2* expression was not significantly associated with overall survival (OS) (*YTHDF1*: MST, 99.4 vs. 70.2 months, P=0.74; *YTHDF2*: MST, 98.4 vs. 64.1 months, P=0.28). According to multivariate analysis, serosal invasion [hazard ratio (HR), 2.39; 95% CI 1.30-4.42; P=0.005], portal vein or hepatic vein invasion (HR, 2.82; 95% CI 1.26-6.28; P=0.01) and *YTHDF2* expression in HCC tissues (HR, 1.85;

95% CI 1.09-3.15; P=0.02) were identified as significant independent prognostic factors for RFS. α -fetoprotein (HR, 1.79; 95% CI 1.10-2.92; P=0.02), serosal invasion (HR, 1.99; 95% CI 1.17-3.34; P=0.01) and portal vein or hepatic vein invasion (HR, 3.02; 95% CI 1.38-6.61; P=0.006) were identified as significant independent prognostic factors for OS. In conclusion, the present study revealed that high *YTHDF2* expression, an m⁶A reader, in HCC tissues was associated with cancer recurrence.

Introduction

Hepatocellular carcinoma (HCC) is the main type of primary liver cancer and is one of the most common malignancies with poor survival (1). Hepatectomy is a potentially curative treatment, but the recurrence rate of HCC after surgery is remarkably high at approximately 70% (2). Therefore, further understanding of the molecular mechanisms of HCC development and recurrence is required.

More than 100 types of chemical modifications have been identified in RNA (3). Recently, internal modifications of mRNA have received attention for their roles in mRNA metabolism. N⁶-methyladenosine (m⁶A) is the most abundant modification of mRNA in eukaryotes and was first reported in the 1970s (4). Recent evidence suggests that m⁶A has various functions in RNA metabolism, such as pre-mRNA splicing, 3'-end processing, nuclear export, translation regulation, regulation of mRNA decay and noncoding RNA processing (5-7). Furthermore, m⁶A methylation has been revealed to have crucial roles in the initiation and progression of cancer (8).

m⁶A readers are the proteins that recognize and bind to m⁶A sites and thereby elicit multiple effects (9). YT521-B homology domain family 2 (*YTHDF2*) was the first identified m⁶A binding protein (10). *YTHDF2* weakens mRNA stability by recognizing m⁶A, while YT521-B homology domain family 1 (*YTHDF1*) promotes mRNA translation efficiency (11). In solid cancer, *YTHDF2* and *YTHDF1* have been reported to have roles as both tumour promoters and suppressors (12-14). However, the significance of *YTHDF1* and *YTHDF2* in oncogenesis remains unclear.

In the current study, we assessed the expression of *YTHDF1* and *YTHDF2* in both resected HCC tissues and paired normal liver tissues collected from patients who underwent surgery

Correspondence to: Dr Fuminori Sonohara, Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa, Nagoya, Aichi 466-8550, Japan
E-mail: fsonohara@med.nagoya-u.ac.jp

*Contributed equally

Key words: hepatocellular carcinoma, methylation of N⁶ adenosine, YTH domain family, prognosis

Table I. Clinicopathological characteristics of patients with hepatocellular carcinoma (n=177).

Characteristics	Value
Median age (range), years	65 (37-84)
Sex, male:female, n (%)	148 (84) : 29 (16)
Viral infection, HBV:HCV:non-HBV/HCV, n (%)	41 (23) : 106 (60) : 30 (17)
Median albumin (range), g/dl	3.9 (2.3-4.9)
Median total bilirubin (range), mg/dl	0.7 (0.2-7.3)
Median PT (range), %	88.7 (46.9-138)
Median ICG-R15 (range), %	11.4 (1.6-70.5)
Child-Pugh classification, A:B, n (%)	166 (94):10 (6)
Liver damage classification, A:B:C, n (%)	142 (83):28 (16):1 (1)
Tumour multiplicity, solitary:multiple, n (%)	138 (78):39 (22)
Median tumour size (range), cm	3.5 (0.15-15)
Median AFP (range), ng/ml	17 (0.8-119923)
Stage, I:II:III:IV, n (%)	19 (11):91 (52):44 (25):21 (12)

PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α -fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.




Figure 1. Relative expression levels of *YTHDF1* and *YTHDF2* in (A) individual and (B) paired hepatocellular carcinoma and adjacent tissues. *YTHDF1/2*, YT521-B homology domain family 1/2; T, tumour; N, non-cancerous.

with curative intent. We also sought to discover novel prognostic implications of m⁶A readers that could be used to predict prognosis in patients with resected HCC.

Patients and methods

Patients and samples. A total of 177 frozen tumour specimens and paired paratumor noncancerous tissues were collected from patients with HCC who underwent surgery at Nagoya University Hospital (Nagoya City, Japan) between January 1998 and April 2014. All fresh tissues were immediately frozen in liquid nitrogen and stored at -80°C until use. Patient characteristics are summarized in Table I. After surgery, all patients were monitored via blood examinations, ultrasonography, and computed tomography once every six months. Angiography was performed for further information whenever recurrence was suspected. The

median follow-up duration of all patients was 48.8 months (range, 0.3 to 191 months). This study and all procedures were approved by the Institutional Review Board at Nagoya University (Nagoya City, Japan), and all patients provided written informed consent. All clinical investigations were conducted in accordance with the principles of the Declaration of Helsinki.

RNA isolation and RT-qPCR. Total RNA was extracted from tissue samples using a Qiagen miRNeasy mini-kit (Qiagen, Hilden, Germany). We used DNase to avoid contamination, and RNA quality was analysed by a NanoDrop (Thermo Scientific Fisher, Waltham, MA, USA). Total RNA was converted to complementary DNA by reverse transcription with M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). This total cDNA was used as a template for the next step of quantitative PCR (qPCR). qPCR was performed using SYBR Premix

Table II. Clinical features of 177 patients with hepatocellular carcinoma according to YTHDF1 and YTHDF2 expression.

Variables	YTHDF1 expression (n=172) ^a		P-value	YTHDF2 expression (n=174) ^b		P-value
	Low (n=108)	High (n=64)		Low (n=137)	High (n=37)	
Age, years						
<65	50	34	0.43	67	18	0.98
≥65	58	30		70	19	
Sex						
Female	14	13	0.28	22	6	0.98
Male	94	51		115	31	
Virus infection						
Others	44	25	0.87	58	13	0.46
HCV	64	39		79	24	
Albumin, g/dl						
≥3.5	85	54	0.54	110	30	0.98
<3.5	22	10		26	7	
NA	1	0		1	0	
PT, %						
≥70	91	57	0.50	114	34	0.29
<70	16	7		22	3	
NA	1	0		1	0	
ICG-R15, %						
<15	58	35	0.91	75	19	0.15
≥15	19	12		21	11	
NA	31	17		41	7	
Liver cirrhosis						
Negative	72	39	0.51	90	20	0.25
Positive	36	25		47	17	
Child-Pugh classification						
A	100	61	0.74	128	35	0.91
B	7	3		8	2	
NA	1	0		1	0	
Liver damage						
A	84	54	0.53	110	29	0.80
B or C	19	9		22	7	
NA	5	1		5	1	
Tumour number						
Solitary	86	48	0.57	109	27	0.38
Multiple	22	16		28	10	
Tumour size, cm						
<2	14	10	0.82	17	6	0.79
≥2	78	50		100	29	
NA	16	4		20	2	
AFP, ng/ml						
<20	58	35	0.91	68	25	0.06
≥20	48	28		67	11	
NA	2	1		2	1	
Differentiation						
Good or moderate	98	56	0.77	121	35	0.08
Poor	8	6		14	0	
NA	2	2		2	2	

Table II. Continued.

Variables	YTHDF1 expression (n=172) ^a		P-value	YTHDF2 expression (n=174) ^b		P-value
	Low (n=108)	High (n=64)		Low (n=137)	High (n=37)	
Growth form						
Expansive	88	54	0.52	114	31	0.42
Infiltrative	18	8		22	3	
NA	2	2		1	3	
Formation of capsule						
Positive	70	52	0.02	97	27	0.84
Negative	38	12		40	10	
Infiltration to capsule						
Negative	52	22	0.08	57	17	0.71
Positive	55	42		79	20	
NA	1	0		1	0	
Septal formation						
Positive	74	42	0.61	98	19	0.02
Negative	31	21		36	17	
NA	3	1		3	1	
Serosal invasion						
Negative	85	50	0.69	107	31	0.81
Positive	19	14		26	6	
NA	4	0		4	0	
Portal vein or hepatic vein invasion						
Negative	80	45	0.60	101	26	0.68
Positive	28	19		36	11	
Surgical margin						
Negative	91	53	0.66	114	31	0.92
Positive	15	11		21	6	
NA	2	0		2	0	
Stage						
<III	65	42	0.62	85	24	0.83
≥III	41	22		50	13	
NA	2	0		2	0	

^aThe data for YTHDF1 expression were not available for 5 patients. ^bThe data for YTHDF2 expression were not available for 3 patients. PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α -fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; NA, not available.

Ex Taq II (Takara Clontech, Kyoto, Japan) under the following conditions: Denaturation at 95°C for 10 sec and 40 cycles of denaturation at 95°C for 5 sec and annealing/extension at 60°C for 30 sec. The SYBR Green signal was detected in real-time using a StepOne Plus Real-Time PCR System (Life Technologies, Carlsbad, CA, USA). The relative quantification method was used, and the expression level of each gene was normalized to the expression level of the control gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) for each sample. The relative gene expression levels were determined using the comparative threshold cycle ($2^{-\Delta CT}$) method.

The PCR primers used in the current study were specific for the 78-base-pair fragment of *YTHDF1* (sense, 5'-TCC

ATCTTCGACGACTTTTGCT-3'; antisense, 5'-TCGACT CTGCCGTTTCCTTG-3') and for the 50-base-pair fragment of *YTHDF2* (sense, 5'-GAGGATCTGAGAGCCATG TCG-3'; antisense, 5'-ATTTTGTACTGCTCCAAGAGGC-3'). *GAPDH* primers (sense, 5'-GAGTCCACTGGCGTCTTC AC-3'; antisense, 5'-GTTACACCCATGACGAACA-3') were used to quantify the expression in each sample as an internal control. The primers were designed as intron spanning. All qPCR experiments were performed in duplicate, including the template-omitted negative controls.

Acquisition of publicly available data. Normalized TCGA RNA-sequencing data of HCC were downloaded from




Figure 2. Kaplan-Meier analysis of (A) recurrence-free survival and (B) overall survival for 177 patients with hepatocellular carcinoma based on *YTHDF1* and *YTHDF2* expression. *YTHDF1/2*, YT521-B homology domain family 1/2.

the Broad GDAC Firehose (<http://gdac.broadinstitute.org/>, accessed on January 1st, 2020). This dataset consists of 50 noncancerous cases and 360 HCC cases, including seven HCC cases mixed with hepatocholangiocarcinoma and two cases with fibrolamellar carcinoma. Of the 360 cases, there were 266 cases with recurrence-free survival (RFS) information and 336 cases with overall survival (OS) information.

Statistical analysis. Continuous variables are expressed as the median (range), and the expression of each target gene was compared by a Wilcoxon signed-rank test and paired t-test. Categorical variables were compared using χ^2 or Fisher's exact tests, as appropriate. The OS and RFS rates at each point of the follow-up time were estimated using the Kaplan-Meier

method and compared using a log-rank test. A Cox proportional hazard regression model was used to perform univariate analysis and multivariate analysis for OS and RFS. In the multivariate analysis, variables that showed statistical significance in the univariate Cox proportional hazard regression were included. All statistical analyses were performed using R version 3.5.3 (<http://www.r-project.org/>), and $P < 0.05$ obtained using two-tailed tests was considered to indicate statistical significance.

Results

YTHDF1 and YTHDF2 in resected specimens from HCC patients. First, expression analyses of m⁶A readers were




Figure 3. Relative (A) *YTHDF1* and (B) *YTHDF2* expression in 360 paired hepatocellular carcinoma tissues and 50 adjacent tissues from TCGA dataset. Survival analysis using Kaplan-Meier curves for recurrence-free survival in TCGA dataset based on (C) *YTHDF1* and (D) *YTHDF2* expression. Survival analysis using Kaplan-Meier curves for overall survival in TCGA dataset based on (E) *YTHDF1* and (F) *YTHDF2* expression. TCGA, The Cancer Genome Atlas; *YTHDF1/2*, YT521-B homology domain family 1/2; T, tumour; N, non-cancerous; RSEM, RNA-Sequencing by Expectation Maximization.

conducted with our surgically resected specimens. The expression levels of *YTHDF1* and *YTHDF2* were measured by qPCR. The expression of *YTHDF1* and *YTHDF2* was not significantly different between tumour tissues and non-cancerous tissues ($P=0.93$ and $P=0.7$, respectively, Fig. 1A). Fig. 1B shows individual changes in *YTHDF1* and *YTHDF2* expression in paired analysis. Based on the results obtained by qPCR, 177 HCC cases were divided into two groups according to *YTHDF1* and *YTHDF2* expression in tumour tissues. We selected the cut-off values that showed the best statistical difference. Clinical features of the groups stratified by *YTHDF1* and *YTHDF2* expression are shown in Table II. In

HCC tissues, low *YTHDF1* expression was associated with a lack of capsule (65% vs. 81%, $P=0.02$), whereas low *YTHDF2* expression was associated with septal formation (73% vs. 53%, $P=0.02$).

Prognostic significance of YTHDF1 and YTHDF2 in resected HCC cases. Next, the effects of the expression levels on RFS and OS were evaluated. In HCC tissues, both high *YTHDF1* expression and high *YTHDF2* expression were significantly correlated with shorter RFS (*YTHDF1*: MST=34.0 vs. 19.0 months, $P=0.014$; *YTHDF2*: MST=30.1 vs. 12.9 months, $P=0.0032$, Fig. 2A), whereas *YTHDF1*

Table III. Univariate and multivariate Cox proportional-hazard regression analysis of recurrence free survival in patients with hepatocellular carcinoma.

Characteristic	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≥65 vs. <65 years	1.01	0.71-1.43	0.98			
Sex, male vs. female	1.27	0.77-2.10	0.35			
Virus infection, HCV vs. others	1.28	0.88-1.85	0.19			
Albumin, <3.5 vs. ≥3.5 g/dl	1.74	1.13-2.68	0.01	1.17	0.59-2.35	0.65
PT, <70 vs. ≥70%	1.12	0.67-1.84	0.67			
ICG-R15, ≥15 vs. <15%	2.06	1.31-3.26	0.002	1.17	0.60-2.29	0.64
Liver cirrhosis, (+) vs. (-)	1.31	0.91-1.88	0.14			
Child-Pugh classification, B vs. A	1.24	0.60-2.53	0.56			
Liver damage, B or C vs. A	1.97	1.26-3.08	0.003	1.91	0.88-4.14	0.10
Tumour number, multiple vs. solitary	1.61	1.07-2.42	0.02	1.44	0.66-3.17	0.35
Tumour size, ≥2 vs. <2 cm	1.73	0.97-3.09	0.06			
AFP, ≥20 vs. <20 ng/ml	1.46	1.02-2.08	0.04	1.43	0.88-2.34	0.15
Differentiation, poor vs. good/moderate	1.58	0.85-2.94	0.15			
Growth form, infiltrative vs. expansive	1.49	0.92-2.42	0.10			
Formation of capsule, (-) vs. (+)	1.27	0.84-1.91	0.25			
Infiltration to capsule, (+) vs. (-)	1.06	0.74-1.51	0.77			
Septal formation, (-) vs. (+)	1.00	0.68-1.47	0.99			
Serosal invasion, (+) vs. (-)	2.00	1.33-3.02	0.0009	2.39	1.30-4.42	0.005
Portal vein or hepatic vein invasion, (+) vs. (-)	2.36	1.57-3.54	<0.001	2.82	1.26-6.28	0.01
Surgical margin, (+) vs. (-)	1.32	0.81-2.13	0.26			
Stage, III/IV vs. I/II	1.46	1.01-2.10	0.04	0.65	0.28-1.51	0.32
YTHDF1 expression, high vs. low	1.60	1.11-2.31	0.01	1.37	0.83-2.27	0.21
YTHDF2 expression, high vs. low	1.82	1.20-2.76	0.004	1.85	1.09-3.15	0.02

PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α -fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; HR, hazard ratio.

expression and *YTHDF2* expression were not correlated with OS (*YTHDF1*: MST=99.4 vs. 70.2 months, $P=0.74$; *YTHDF2*: MST=98.4 vs. 64.1 months, $P=0.28$, Fig. 2B).

YTHDF1 and *YTHDF2* expression levels and their correlation with HCC prognosis in a publicly available dataset

We analysed the expression levels of *YTHDF1* and *YTHDF2* in HCC and noncancerous tissues using a TCGA RNA-sequence dataset. This analysis revealed that the expression of *YTHDF1* was significantly higher in HCC tumour tissues and that *YTHDF2* expression was significantly lower in HCC tumour tissues than in noncancerous tissues (*YTHDF1*, $P=0.0011$; *YTHDF2*, $P=0.025$, Fig. 3A and B). We then confirmed the prognostic impact of *YTHDF1* and *YTHDF2* expression in resected HCC patients using the same TCGA dataset. HCC cases were divided into two groups according to the *YTHDF1* and *YTHDF2* expression in HCC tissues in the normalized RNA-sequencing data. We also selected the cut-off values that showed the best statistical difference. This analysis revealed that the patients with high *YTHDF1* expression had significantly worse RFS (MST=754 vs. 489 days, $P=0.006$, Fig. 3C), and the patients with high *YTHDF2* expression tended to have worse RFS (MST=636 vs. 315 days, $P=0.06$, Fig. 3D). In addition, the patients with high *YTHDF1* expression had

significantly worse OS (MST=2456 vs. 1,372 days, $P=0.015$, Fig. 3E), and the patients with high *YTHDF2* expression had significantly worse OS (MST=2,456 vs. 724 days, $P=0.0002$, Fig. 3F).

Cox regression analysis of HCC survival. Since the survival curves showed that *YTHDF1* and *YTHDF2* expression levels in HCC tissues were correlated with RFS, we performed Cox proportional hazards analyses to further investigate the prognostic value of *YTHDF1* and *YTHDF2* expression. The multivariate analysis identified serosal invasion (hazard ratio (HR): 2.39, 95% confidence interval (95% CI): 1.30-4.42, $P=0.005$), portal vein or hepatic vein invasion (HR, 2.82, 95% CI: 1.26-6.28, $P=0.01$) and *YTHDF2* expression in HCC tissues (HR, 1.85, 95% CI: 1.09-3.15, $P=0.02$) as significant independent factors for RFS (Table III) and AFP (HR, 1.79, 95% CI: 1.10-2.92, $P=0.02$), serosal invasion (HR, 1.99, 95% CI: 1.17-3.34, $P=0.01$), and portal vein or hepatic vein invasion (HR, 3.02, 95% CI: 1.38-6.61, $P=0.006$) as significant independent factors for OS (Table IV). Consequently, high expression of *YTHDF2* in HCC tissues was significantly associated with recurrence after HCC surgery.

Table IV. Univariate and multivariate cox proportional-hazard regression analysis of overall survival in patients with hepatocellular carcinoma.

Characteristic	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≥ 65 vs. < 65 years	1.34	0.87-2.06	0.18			
Sex, female vs. male	1.01	0.57-1.80	0.96			
Virus infection, HCV vs. others	1.32	0.84-2.07	0.23			
Albumin, < 3.5 vs. ≥ 3.5 g/dl	1.75	1.05-2.92	0.03	1.34	0.63-2.85	0.45
PT, < 70 vs. $\geq 70\%$	1.51	0.87-2.61	0.14			
ICG-R15, ≥ 15 vs. $< 15\%$	1.69	0.95-2.98	0.07			
Liver cirrhosis, (+) vs. (-)	1.38	0.90-2.13	0.14			
Child-Pugh classification, B vs. A	1.33	0.58-3.06	0.50			
Liver damage, B or C vs. A	2.08	1.24-3.49	0.005	1.73	0.80-3.75	0.16
Tumour number, multiple vs. solitary	1.86	1.16-2.97	0.009	1.63	0.81-3.29	0.17
Tumour size, ≥ 2 vs. < 2 cm	1.78	0.82-3.89	0.14			
AFP, ≥ 20 vs. < 20 ng/ml	2.30	1.48-3.58	0.0002	1.79	1.10-2.92	0.02
Differentiation, poor vs. good/moderate	2.02	1.04-3.93	0.04	1.18	0.50-2.76	0.71
Growth form, infiltrative vs. expansive	1.69	0.99-2.90	0.05			
Formation of capsule, (-) vs. (+)	1.03	0.64-1.66	0.89			
Infiltration to capsule, (-) vs. (+)	1.10	0.71-1.70	0.66			
Septal formation, (-) vs. (+)	1.04	0.65-1.65	0.87			
Serosal invasion, (+) vs. (-)	1.90	1.17-3.09	0.008	1.99	1.17-3.34	0.01
Portal vein or hepatic vein invasion, (+) vs. (-)	2.55	1.61-4.05	< 0.001	3.02	1.38-6.61	0.006
Surgical margin, (+) vs. (-)	1.77	1.04-3.02	0.04	1.68	0.90-3.13	0.10
Stage, III/IV vs. I/II	1.68	1.09-2.59	0.02	2.22	0.91-5.42	0.08
YTHDF1 expression, high vs. low	1.22	0.78-1.90	0.38			
YTHDF2 expression, high vs. low	1.48	0.90-2.43	0.12			

PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α -fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; HR, hazard ratio.

Discussion

In this study, we primarily evaluated the clinical effects of m⁶A readers in resected HCC patients. The expression of *YTHDF1* and *YTHDF2* in HCC tissues was correlated with tumour recurrence. Furthermore, *YTHDF2* was an independent prognostic factor in resected HCC patients. Members of the YT521-B homology (YTH) domain family, including *YTHDF1*, *YTHDF2*, *YTHDF3*, *YTHDC1* and *YTHDC2*, all have a conserved m⁶A-binding domain and preferentially bind to m⁶A-modified RNA at the RRm6ACH consensus sequence (15). *YTHDF2*, the first characterized m⁶A reader, accelerates the decay of m⁶A-modified transcripts by facilitating the recruitment of the CCR4-NOT complex directly (10). In contrast, *YTHDF1* was initially demonstrated to bind to m⁶A sites around the stop codon and then cooperate with the translation initiation machinery to improve the translation efficacy of target RNAs in mammals (11).

We first compared the expression levels of *YTHDF1* and *YTHDF2* in HCC and noncancerous liver tissues from patients who underwent hepatectomy with curative intent at

our institution. Neither *YTHDF1* expression nor *YTHDF2* expression was significantly different between HCC tissues and noncancerous tissues. In the paired analysis, patients with high expression in tumour tissues tended to have low expression in noncancerous tissues. In another cohort in the TCGA RNA-sequence dataset, however, the expression of *YTHDF1* was found to be significantly higher in HCC tissues, and *YTHDF2* was significantly lower in HCC tissues. Li *et al* reported that upregulation of *YTHDF2* was observed in TCGA prostate cancer tissues compared with normal controls (16). Bai *et al* also reported that *YTHDF1* is significantly upregulated in tumour compared with adjacent normal tissues in colorectal cancer (17). In the TCGA dataset, there were relatively small numbers of noncancerous tissues available, but we studied the expression of *YTHDF1* and *YTHDF2* in both tumour and noncancerous tissues from 177 HCC patients. This might have caused the discrepancy in results between the TCGA cases and our cases. In addition, our data showed that the reader expression in tumour tissues was different from that in noncancerous tissues. This change could be more important than the absolute value. In addition, the prognostic analysis stratified by *YTHDF1* and *YTHDF2*

expression in our study revealed that the expression of these two m⁶A readers in HCC tissues is not associated with OS. On the other hand, high expression of both *YTHDF1* and *YTHDF2* in HCC tissues was associated with significantly worse RFS. In the public dataset, high expression of *YTHDF1* or *YTHDF2* was associated with worse prognosis than low expression. In particular, our Cox regression analysis showed that *YTHDF2* was an independent risk factor for recurrence in resected HCC. Thus, *YTHDF1* and *YTHDF2* might have inherent effects in HCC carcinogenesis and influence the long-term outcome after HCC resection, for example, by causing sporadic recurrence.

Evidence of RNA modifications in cancer development and progression has been increasing. The RNA methyltransferase *METTL3* is the first characterized component of the m⁶A methyltransferase complex. *METTL3* promotes tumour proliferation and invasion in several cancers (18-22). The m⁶A demethylases *FTO* and *ALKBH5* were identified in the 2010s. *FTO* and *ALKBH5* also play an important role in human cancer (23-25). However, the functions of *YTHDF1* and *YTHDF2* in HCC have not been uncovered. Zhao *et al* reported that *YTHDF1* played a vital role in the regulation of HCC metabolism (26). Qu *et al* reported that m⁶A RNA methylation modulators, including *YTHDF1*, affected OS in HCC patients (27). *YTHDF2* was able to degrade both tumour promoter and suppressor gene mRNAs. Zhang *et al* reported that *YTHDF2* promotes the cancer stem cell liver phenotype and cancer metastasis by modulating the m⁶A methylation of OCT4 mRNA (28). In contrast, *YTHDF2* may act as a tumour suppressor to repress cell proliferation and growth by destabilizing EGFR mRNA in HCC (29). Further investigations are required to reveal the role of *YTHDF1* and *YTHDF2* in HCC.

Although we showed important aspects of *YTHDF1* and *YTHDF2*, there are some inherent limitations to the present study. First, more data are necessary because we used specimens from a single institute in this study. Second, more detailed molecular mechanisms through which specific m⁶A methylation enhances HCC development need to be discovered. Further investigation is necessary before the clinical utility of our findings can be determined.

In conclusion, our study revealed that high *YTHDF2* expression in HCC tissues is related to cancer recurrence. Our results may pave the way for discovering the clinical utility of m⁶A methylation and associated genes in HCC therapy in the future.

Acknowledgements

The authors would like to thank Dr Raju Kandimalla (Bristol Myers Squibb, San Diego, CA, USA) for useful discussions and Ms. Yoko Nishikawa (Nagoya University Graduate School of Medicine, Nagoya, Japan) for technical assistance with the experiments.

Funding

The present study was partly supported by the Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research (grant nos. 18H06176 and 19K18110).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

NN, FS and YK conceived and designed the study. FS and YK provided financial support. SY and YK provided administrative support. SY, FS, YS, YI, HT, MH, MKa, CT, GN and MKo provided study materials and patients. SY, FS, YS, YI, HT, MH, MKa, CT, GN and MKo assisted with analyses and manuscript preparation. NN, FS, KT and YS collected and assembled the data. NN and KT performed quantitative PCR data analysis and interpretation. NN, FS and YK wrote the manuscript and confirmed the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study and all procedures were approved by the Institutional Review Board at Nagoya University (approval no. 2013-0295; Nagoya, Japan), and all patients provided written informed consent. All clinical investigations were conducted in accordance with the principles of the Declaration of Helsinki.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. *CA Cancer J Clin* 70: 7-30, 2020.
2. Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. *Ann Surg* 261: 947-955, 2015.
3. Roundtree IA, Evans ME, Pan T and He C: Dynamic RNA modifications in gene expression regulation. *Cell* 169: 1187-1200, 2017.
4. Adams JM and Cory S: Modified nucleosides and bizarre 5'-termini in mouse myeloma mRNA. *Nature* 255: 28-33, 1975.
5. Camper SA, Albers RJ, Coward JK and Rottman FM: Effect of undermethylation on mRNA cytoplasmic appearance and half-life. *Mol Cell Biol* 4: 538-543, 1984.
6. Finkel D and Groner Y: Methylations of adenosine residues (m⁶A) in pre-mRNA are important for formation of late simian virus 40 mRNAs. *Virology* 131: 409-425, 1983.
7. Gilbert WV, Bell TA and Schaening C: Messenger RNA modifications: Form, distribution, and function. *Science* 352: 1408-1412, 2016.
8. Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, Yuan W, Kan Q and Sun Z: The interplay between m⁶A RNA methylation and noncoding RNA in cancer. *J Hematol Oncol* 12: 121, 2019.
9. Allis CD and Jenuwein T: The molecular hallmarks of epigenetic control. *Nat Rev Genet* 17: 487-500, 2016.
10. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J and Wu L: YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. *Nat Commun* 7: 12626, 2016.
11. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H and He C: N(6)-methyladenosine modulates messenger RNA translation efficiency. *Cell* 161: 1388-1399, 2015.

12. Chen J, Sun Y, Xu X, Wang D, He J, Zhou H, Lu Y, Zeng J, Du F, Gong A and Xu M: YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. *Cell Cycle* 16: 2259-2271, 2017.
13. Nishizawa Y, Konno M, Asai A, Koseki J, Kawamoto K, Miyoshi N, Takahashi H, Nishida N, Haraguchi N, Sakai D, *et al*: Oncogene c-Myc promotes epitranscriptome m⁶A reader YTHDF1 expression in colorectal cancer. *Oncotarget* 9: 7476-7486, 2018.
14. Shi Y, Fan S, Wu M, Zuo Z, Li X, Jiang L, Shen Q, Xu P, Zeng L, Zhou Y, *et al*: YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. *Nat Commun* 10: 4892, 2019.
15. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, *et al*: N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505: 117-120, 2014.
16. Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, *et al*: YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. *Mol Cancer* 19: 152, 2020.
17. Bai Y, Yang C, Wu R, Huang L, Song S, Li W, Yan P, Lin C, Li D and Zhang Y: YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. *Front Oncol* 9: 332, 2019.
18. Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, *et al*: METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. *Mol Cancer* 18: 110, 2019.
19. Lin S, Choe J, Du P, Triboulet R and Gregory RI: The m(6)A Methyltransferase METTL3 promotes translation in human cancer cells. *Mol Cell* 62: 335-345, 2016.
20. Miao W, Chen J, Jia L, Ma J and Song D: The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. *Biochem Biophys Res Commun* 516: 719-725, 2019.
21. Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, *et al*: METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. *Gut* 69: 1193-1205, 2020.
22. Xia T, Wu X, Cao M, Zhang P, Shi G, Zhang J, Lu Z, Wu P, Cai B, Miao Y and Jiang K: The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. *Pathol Res Pract* 215: 152666, 2019.
23. Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, Zheng H and Li B: The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. *Biochem Biophys Res Commun* 512: 479-485, 2019.
24. Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, *et al*: RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. *Mol Cancer* 18: 46, 2019.
25. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Böglér O, *et al*: m⁶A Demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. *Cancer Cell* 31: 591-606.e6, 2017.
26. Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. *Cancer Biomark* 21: 859-868, 2018.
27. Qu N, Qin S, Zhang X, Bo X, Liu Z, Tan C, Wen G and Jiang H: Multiple m⁶A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis. *BMC Cancer* 20: 165, 2020.
28. Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, Ji F, Ma Z, Hou B and He X: YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. *Oncogene* 39: 4507-4518, 2020.
29. Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H and Kang T: YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. *Cancer Lett* 442: 252-261, 2019.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.